At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
sildenafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease
In Brief
A Phase 2 clinical trial evaluating sildenafil and placebo for Cystic Fibrosis. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This study evaluates the ability of the drug sildenafil to improved exercise capacity, cardiac performance during exercise, and quality of life in patients with moderate to severe CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedDec 2015
Primary CompletionJan 2018
Study CompletionJan 2018
TodayJul 2026
First PostedDec 10, 2015
Enrollment StartDec 1, 2015
Primary CompletionJan 18, 2018
Study CompletionJan 29, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.6 years ago
Interventions
sildenafildrug
active sildenafil
placebodrug
sugar pill that looks like sildenafil tablets